All serious adverse events · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use
It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes all serious adverse events compared with fresh frozen plasma (very low certainty).
1 finding from 1 review
RR 0.27 [0.02, 3.74]
1 study · 5 participants
Very low
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention Multimodal/complex intervention, ATCS Plus, IVR versus various controls · participants at risk of developing long‐term conditions
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention Multimodal/complex intervention, ATCS Plus, IVR versus various controls · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention Multimodal/complex intervention, ATCS Plus, IVR versus various controls · patients with tobacco dependence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention Multimodal/complex intervention, ATCS Plus, IVR, unidirectional versus various controls · participants at risk for breast, colorectal or cervical cancer; or osteoporosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention Multimodal/complex intervention, ATCS Plus, IVR, unidirectional versus various controls · patients with various conditions or at risk of low adherence to medication or laboratory tests
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention Multimodal/complex intervention, ATCS Plus, IVR, unidirectional ATCS versus various controls · patients with hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · parents and carers of children with complex needs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · parents and carers of children with complex needs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · adults with complex regional pain syndrome type 1 (lower limb)
1 finding from 1 review
no estimate extracted
20 participants
Very low
Intervention not reported
Adverse events · people with TSC
The intervention probably leads to higher adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events · people with TSC
The intervention leads to higher adverse events (high certainty).
1 finding from 1 review
Adverse events · cardiac surgery for the treatment of non‐surgical bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · cardiac surgery for the treatment of non‐surgical bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review